Price Forecast:

Bullish Case: Regeneron's approval of Eylea biosimilars and Dupixent in COPD positions it positively for revenue growth. Continued investor interest and favorable regulatory outcomes could drive stock upward amid its historical resilience.

Bearish Case: Competitive pressures from biosimilars and pending litigation may hinder Regeneron's market position. Recent mean-reverting tendencies and elevated volatility could lead to price declines if FDA approvals fall through.

Potential Outcomes:

1. FDA approvals drive growth (60%)
2. Continued competitive pressures result in price decline (25%)
3. Stocks stabilize amid neutral market trends (15%)

Trading Oracle: Consider initiating a bullish debit spread with a long position at $800 and short at $750, targeting December expiration, capitalizing on low implied volatility and capturing potential price recovery as market sentiment stabilizes.

November 23, 2024